Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Can gene expression help to pick the right biologic to treat psoriasis in cancer patients? Next Article
IL-4/IL-13 blocker dupilumab effective in children with severe AD »
« Can gene expression help to pick the right biologic to treat psoriasis in cancer patients? Next Article
IL-4/IL-13 blocker dupilumab effective in children with severe AD »
Table of Contents: AAD 2020
Featured articles
Late-Breaking Abstracts
IL-17A and IL-17F blockade remarkably effective in psoriasis
Good response and pruritus reduction in AD with novel selective JAK1 inhibitor
Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis
Tape stripping – a painless way to distinguish AD and psoriasis?
IL-4/IL-13 blocker dupilumab effective in children with severe AD
Pembrolizumab leads to higher toxicity risk in obese melanoma patients
Can gene expression help to pick the right biologic to treat psoriasis in cancer patients?
Omalizumab for cancer-induced dermatoses
Psoriasis – What Is Hot?
Psoriasis therapy for children and pregnancies
Biologic psoriasis treatment to lower cardiovascular risk?
Systemic Therapies for Dermatologists
How to manage cutaneous side effects of immunotherapy
Cannabinoids: a future role in dermatology?
Hidradenitis Suppurativa/Acne Inversa
Biologics in HS – a growing armamentarium
Pearls of the Posters
Selective IL-23 blocker safe in elderly psoriasis patients
Spironolactone safe for androgenetic alopecia in cancer survivors
Baricitinib beneficial in head and neck AD
ECLIPSE trial: skin clearance independent of PsA status at baseline
Related Articles
August 6, 2020
IL-13 blocker tralokinumab effective in AD
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy